Multiple System Atrophy (MSA) Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)

Multiple System Atrophy (MSA) Market is Segmented By Subtype (MSA-Parkinsonian, MSA-Cerebellar), By Diagnosis (Clinical Diagnosis, Biomarker-Based Diagnosis, Imaging-Based Diagnosis), By Treatment (Pharmacological Therapies, Non-Pharmacological Therapies), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.

Multiple System Atrophy (MSA) Market Leaders

  • Chelsea Therapeutics International, Ltd.
  • Biohaven Pharmaceuticals, Inc.
  • Sumitomo Dainippon Société d'assurance-vie
  • AstraZeneca plc
  • Theravance Biopharma, Inc.
*Disclaimer: Major players are listed in no particular order.

Multiple System Atrophy (MSA) Market - Company List

  • Chelsea Therapeutics International, Ltd.
  • Biohaven Pharmaceuticals, Inc.
  • Sumitomo Dainippon Société d'assurance-vie
  • AstraZeneca plc
  • Theravance Biopharma, Inc.
  • La société Merck & Co.
  • Neuropore Therapies Inc.
  • Newron Pharmaceuticals SpA
  • ProMIS Neurosciences Inc.
  • Biothérapeutiques de vol Société
  • Agence européenne pour l'environnement
  • Corestem Inc.
  • MitoDys Therapeutics Ltd.
  • La société Modag GmbH
  • Acadia Pharmaceuticals Inc.
  • Novartis AG
  • Sanofi S.A.
  • Teva Pharmaceutique Industries Ltd.
  • Eli Lilly et la société
  • Johnson et Johnson

Multiple System Atrophy (MSA) Market Report Snapshots

Buy Now